Vaxart (VXRT) announced that on November 15, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 91,500 shares of its common stock
Vaxart (VXRT) announced that on November 15, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 91,500 shares of its common stock
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Vaxart (VXRT – Research Report) yesterday and set a price target of $2.50. Mayank Mamtani has given his Buy rating
In a report released today, Cheng Li from Oppenheimer maintained a Buy rating on Vaxart (VXRT – Research Report), with a price target of $4.00. The company’s shares closed yesterday
Vaxart ( ($VXRT) ) has released its Q3 earnings. Here is a breakdown of the information Vaxart presented to its investors. Vaxart, Inc. is a clinical-stage biotechnology company specializing in
Reports Q3 revenue $4.93M, consensus $850,000. “Our successful initiation of sentinel cohort dosing is a testament to our rapid execution in helping to ensure that we remain on track to